A61K 51/1033
Against receptors for cytokines, lymphokines or interferons
Official title: {against receptors for cytokines, lymphokines or interferons}
A61K51/1033 (Against receptors for cytokines, lymphokines or interferons) appears on 33 US grants and 54 published applications in this corpus.
Search patents in A61K- Granted patents
- 33
- Published applications
- 54
- Assignees
- 36
- Inventors
- 112
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 1 | 2 |
| 2005 | 0 | 1 |
| 2006 | 1 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 2 | 3 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 2 | 3 |
| 2014 | 4 | 4 |
| 2015 | 1 | 6 |
| 2016 | 3 | 0 |
| 2017 | 5 | 2 |
| 2018 | 3 | 4 |
| 2019 | 3 | 3 |
| 2020 | 0 | 5 |
| 2021 | 1 | 1 |
| 2022 | 1 | 2 |
| 2023 | 1 | 3 |
| 2024 | 1 | 2 |
| 2025 | 0 | 3 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Human 4-1BB agonist antibodies and methods of use thereof9 Jun 2026US 12,649,797 B2Board of Regents, The University of Texas System
- Methods for treatment of patients with myelodysplastic syndromes10 Sep 2024US 12,083,192 B2Actinium Pharmaceuticals, Inc.
- Anti-IL1RAP antibodies and their use for treating humans3 Oct 2023US 11,773,174 B2Cantargia AB
- Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions27 Dec 2022US 11,534,496 B2The Brigham and Women S Hospital, Inc.
- Methods of detecting a solid tumor with anti-IL1RAP antibodies4 May 2021US 10,995,144 B2Cantargia AB
- Anti-cd40 antibody and use thereof10 Sep 2026US 2026/0265391 A1Biotheus Inc.
- Anti-cd25 antigen-binding proteins and uses thereof3 Sep 2026US 2026/0258143 A1Odyssey Therapeutics, Inc.
- Human 4-1bb agonist antibodies and methods of use thereof30 Jul 2026US 2026/0217846 A1Board of Regents, The University of Texas System
- Antibody mono-or multi-specific to ephrin type-a receptor 10, chimeric antigen receptor t-cell expressing the same and uses thereof22 Jan 2026US 2026/0022179 A1China Medical University
- Anti-cd90 antibodies, binding fragments, and uses thereof7 Aug 2025US 2025/0249125 A1Fred Hutchison Cancer Center
Most cited
By later US patents
- Methods to impair hematologic cancer progenitor cells and compounds related thereto72US 6,733,743 B2University of Kentucky Research Foundation · 2004
- Methods for diagnosis using anti-cytokine receptor antibodies62US 7,727,528 B2Early Detection, LLC · 2010
- Diagnosis and/or therapy of tumours using monoclonal antibodies specific for the human IL-4 receptor47US 5,985,280 ARoyal Postgraduate Medical School of Hammersmith Hospital · 1999
- Compounds for diagnosis and/or therapy of tumours44US 6,156,877 ARoyal Postgraduate Medical School of Hammersmith Hospital · 2000
- Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy31US 5,399,338 AUniversity of New Mexico · 1995